TG Therapeutics, Inc. (NASDAQ:TGTX) Receives Average Recommendation of “Moderate Buy” from Brokerages

TG Therapeutics, Inc. (NASDAQ:TGTX) has been assigned an average recommendation of “Moderate Buy” from the six research firms that are presently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $37.67.

Several research analysts have recently issued reports on TGTX shares. The Goldman Sachs Group lifted their price target on TG Therapeutics from $20.00 to $22.00 and gave the stock a “neutral” rating in a research note on Tuesday. HC Wainwright upped their price target on shares of TG Therapeutics from $49.00 to $55.00 and gave the company a “buy” rating in a report on Tuesday. B. Riley raised their price objective on shares of TG Therapeutics from $29.00 to $34.00 and gave the stock a “buy” rating in a research note on Wednesday, August 7th. Finally, TD Cowen assumed coverage on TG Therapeutics in a report on Tuesday, October 29th. They set a “buy” rating and a $50.00 target price on the stock.

TG Therapeutics Stock Performance

Shares of TGTX opened at $27.17 on Thursday. The company has a quick ratio of 2.83, a current ratio of 3.58 and a debt-to-equity ratio of 0.58. TG Therapeutics has a 52-week low of $9.81 and a 52-week high of $27.67. The company has a 50-day simple moving average of $23.57 and a 200-day simple moving average of $20.26. The company has a market capitalization of $4.21 billion, a PE ratio of -271.70 and a beta of 2.19.

TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings results on Monday, November 4th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.01). TG Therapeutics had a net margin of 27.60% and a return on equity of 57.73%. The company had revenue of $83.90 million for the quarter, compared to analyst estimates of $81.68 million. During the same quarter in the previous year, the business posted $0.73 earnings per share. TG Therapeutics’s revenue was down 49.4% on a year-over-year basis. Equities research analysts predict that TG Therapeutics will post 0.13 earnings per share for the current fiscal year.

Hedge Funds Weigh In On TG Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. NBC Securities Inc. raised its stake in TG Therapeutics by 58.9% during the third quarter. NBC Securities Inc. now owns 1,309 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 485 shares during the period. Quarry LP lifted its holdings in shares of TG Therapeutics by 9.1% in the 2nd quarter. Quarry LP now owns 6,003 shares of the biopharmaceutical company’s stock worth $107,000 after purchasing an additional 503 shares during the last quarter. Private Advisor Group LLC grew its stake in TG Therapeutics by 3.9% during the 3rd quarter. Private Advisor Group LLC now owns 14,407 shares of the biopharmaceutical company’s stock worth $337,000 after buying an additional 542 shares during the last quarter. Blue Trust Inc. boosted its holdings in shares of TG Therapeutics by 127.3% during the third quarter. Blue Trust Inc. now owns 1,516 shares of the biopharmaceutical company’s stock valued at $35,000 after acquiring an additional 849 shares during the period. Finally, KBC Group NV grew its position in shares of TG Therapeutics by 30.5% during the third quarter. KBC Group NV now owns 4,675 shares of the biopharmaceutical company’s stock worth $109,000 after acquiring an additional 1,092 shares during the last quarter. 58.58% of the stock is owned by institutional investors and hedge funds.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.